Journal Club（ゼミ）
Journal Club 抄読リスト
2017年度
| 7月～ Marsh K, Goetghebeur M, Thokala P et al. Multi-Criteria Decision Analysis to Support Healthcare Decisions. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, editors. Cham: Springer; 2017. |
担当：全室員分担 |
2016年度
| 1月17日 Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder. A Systematic Literature Review. CNS Drugs. 2012;26(7):581-600. |
担当：前田 |
| 1月9日 Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res. 2013;22(3):683-694. |
担当：船越 |
| 12月20日 Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health. 2012;15:835-842. |
担当：下妻 |
| 12月13日 Elvidge J, Bullement A, Hatswell AJ. Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK. Pharmacoeconomics. 2016; 34(11): 1145-1159. |
担当：村澤 |
| 12月6日 Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014; 32(2): 101-108. |
担当：竹田 |
| 11月29日 Hernández Alava M, Wailoo A, Wolfe F, Michaud K. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making. 2014 Oct;34(7):919-930. |
担当：船越 |
| 11月22日 Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. |
担当：竹田 |
| 11月15日 Petrou S, Rivero-Arias O, Dakin H et al. Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Pharmacoeconomics. 2015; 33(10): 985-991. Petrou S, Rivero-Arias O, Dakin H et al. The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. Pharmacoeconomics. 2015; 33(10): 993-1011. |
担当：下妻 |
| 11月8日 Sallee FR, McGough J, Wigal T et al., Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009; 48(2):155-65. |
担当：前田 |
| 10月25日 Sanders GD, Neumann PJ, Basu A et al., Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016; 316(10):1093-1103. |
担当：村澤 |
| 10月18日 Kongnakorn T, Ward A, Roberts CS et al., Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health. 2009; 12(6): 880-887. |
担当：船越 |
| 10月11日 Saad F, Carles J, Gillessen S et al., Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016; 17(9): 1306-1316. |
担当：竹田 |
| 10月3日 Lachaine J, Sikirica V, Mathurin K. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD. BMC Psychiatry. 2016; 16: 11. |
担当：前田 |
| 9月27日 Airoldi M, Morton A, Smith JA et al., STAR--people-powered prioritization: a 21st-century solution to allocation headaches. Med Decis Making 2014; 34(8): 965-75. |
担当：船越 |
| 7月19日 Ahlert M, Breyer F, Schwettmann L. How you ask is what you get: Framing effects in willingness-to-pay for a QALY. Soc Sci Med 2016; 150: 40-48. |
担当：村澤 |
| 7月12日 Krol M, Stolk E, Brouwer W. Predicting productivity based on EQ-5D: an explorative study. Eur J Health Econ 2014; 15(5): 465-475. |
担当：船越 |
| 7月5日 Cella D, Grünwald V, Nathan P et al., Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17(7): 994–1003. |
担当：下妻 |
| 6月28日 Diels J, Hamberg P, Ford D et al., Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Qual Life Res 2015; 24(3): 591-598. |
担当：竹田 |
| 6月21日 Sikirica V, Haim Erder M, Xie J et al. Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents. Pharmacoeconomics 2012; 30(8): e1-e15. |
担当：前田 |
| 6月14日 Chen P, Lin KC, Liing RJ, Wu CY et al., Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation. Qual Life Res 2016; 25(6): 1585-1596. |
担当：下妻 |
| 6月7日 Pélissier C, Vohito M, Fort E et al., Risk factors for work-related stress and subjective hardship in health-care staff in nursing homes for the elderly: A cross-sectional study. J Occup Health 2015; 57(3): 285-296. |
担当：村澤 |
| 5月31日 Hummel MJ, Volz F, van Manen JG et al., Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment. Patient 2012; 5(4):225-327. |
担当：船越 |
| 5月24日 Nilsson S, Cislo P, Sartor O, et al., Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of Oncology 2012: 1-7. |
担当：竹田 |
| 5月17日 Erder MH, Xie J, Signorovitch JE et al., Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2012; 10(6): 381-95. |
担当：前田 |
| 5月10日 Cicolini G, Pelle CD, Cerratti F, et al., Validation of the Italian version of the Stanford Presenteeism. J Nurs Manag, 2016; 1: 1-7. |
担当：村澤 |
| 4月26日 Ospina MB, Dennett L, Waye A et al., A systematic review of measurement properties of instruments assessing presenteeism. Am J Manag Care. 2015; 21(2): e171-85. |
担当：下妻 |
| 4月19日 Marsh K, IJzerman M, Thokala P et al., Multiple Criteria Decision Analysis for Health Care Decision Making-Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 2016; 19(2): 125-37. |
担当：船越 |